Dysfunction of retinal neurons and glia during diabetes

Clinical and Experimental Optometry

Volumn 88, Issue 3, 2005, Pages 132-145

  Fletcher, Erica L ^a   Phipps, Joanna A ^a   Wilkinson Berka, Jennifer L ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Astrocyte; Diabetes; M ller cell; Pericyte; Renin; VEGF

Indexed keywords

ANIMAL; DIABETIC RETINOPATHY; GLIA; HUMAN; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; RETINA; REVIEW;

ANIMALS; DIABETIC RETINOPATHY; HUMANS; NEUROGLIA; NEURONS; RETINA;

EID: 23044438696     PISSN: 08164622     EISSN: 14440938     Source Type: Journal    
DOI: 10.1111/j.1444-0938.2005.tb06686.x     Document Type: Review

References (164)

1. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997; 14 Suppl 5: S1-S85.
2. Aiello LP, Gardner TW, King GL, Blankenship G, Cavallerano JD, Ferris FL 3rd, Klein R. Diabetic retinopathy. Diabetes Care 1998; 21: 143-156.
3. Colagiuri S, Colagiuri R, Ward J. Report of the Australian National Diabetes Strategy and Implementation Plan. 1998.
4. UKPDS. Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
5. DCCT. Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Diabetes 1993; 46: 271-286.
6. Engerman RL, Kern TS. Progression of incipient diabetic retinopathy during good glycemic control. Diabetes 1987; 36: 808-812.
7. Su E-N, Alder VA, Yu D-Y, Yu PK, Cringle SJ, Yogesan K. Continued progression of retinopathy despite spontaneous recovery to normoglycemia in a long-term study of stretozotocin-induced diabetes in rats. Graefes Arch Clin Exp Ophthalmol 2000; 238: 163-173.
8. Hirschi KK, D'Amore PA. Pericytes in the microvasculature. Cardiovasc Res 1996; 32: 687-698.
9. Engerman RL. Pathogenesis of diabetic retinopathy. Diabetes 1989; 38: 1203-1206
10. Denis U, Lecomte M, Paget C, Ruggiero D, Wiernsperger N, Lagarde M. Advanced glycation end-products induce apoptosis of bovine retinal pericytes in culture: involvement of diacylglycerol/ceramide production and oxidative stress induction. Free Radic Biol Med 2002; 33: 236-247.
11. Nayak RC, Agardh CD, Kwok MG, Stjernquist H, Farthing-Nayak PJ, Agardh E. Circulating anti-pericyte autoantibodies are present in Type 2 diabetic patients and are associated with non-proliferative retinopathy. Diabetologia 2003; 46: 511-513.
12. Attawia MA, Nayak RC. Circulating antipericyte autoantibodies in diabetic retinopathy. Retina 1999; 19: 390-400.
13. McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist 2000; 5 Suppl 1: 3-10.
14. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 2001; 280: C1358-C1366.
15. Caldwell RB, Bartoli M, Behzadian MA, El-Remessy AE, Al-Shabrawey M, Platt DH, Caldwell RW. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 2003; 19: 442-455.
16. Witmer AN, Blaauwgeers HG, Weich HA, Alitalo K, Vrensen GF, Schlingemann RO. Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey. Invest Ophthalmol Vis Sci 2002; 43: 849-857.
17. Stone J, Itin A, Alon T, Pe'er J, Gnessin H, Chan-Ling T, Keshet E. Development of retinal vasculature is mediated by hypoxiainduced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 1995; 15: 4738-4747.
18. Sandercoe TM, Geller SF, Hendrickson AE, Stone J, Provis JM. VEGF expression by ganglion cells in central retina before formation of the foveal depression in monkey retina: evidence of developmental hypoxia. J Comp Neurol 2003; 462: 42-54.
19. Provis JM, Leech J, Diaz CM, Penfold PL, Stone J, Keshet E. Development of the human retinal vasculature: cellular relations and VEGF expression. Exp Eye Res 1997; 65: 555-568.
20. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996;380(6573):435-439.
21. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-1487.
22. Sone H, Kawakami Y, Okuda Y, Sekine Y, Honmura S, Matsuo K, Segawa T, Suzuki H, Yamashita K. Ocular vascular endothelial growth factor levels in diabetic rats are elevated before observable retinal proliferative changes. Diabetologia 1997; 40: 726-730.
23. Hofman P, Blaauwgeers HG, Vrensen GF, Schlingemann RO. Role of VEGF-A in endothelial phenotypic shift in human diabetic retinopathy and VEGF-A-induced retinopathy in monkeys. Ophthalmic Res 2001; 33: 156-162.
24. Boulton M, Foreman D, Williams G, McLeod D. VEGF localisation in diabetic retinopathy. Br J Ophthalmol 1998; 82: 561-568.
25. Amin RH, Frank RN, Kennedy A, Eliott D, Puklin JE, Abrams GW. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with non-proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 1997; 38: 36-47.
26. Gerhardinger C, Brown LF, Roy S, Mizutani M, Zucker CL, Lorenzi M. Expression of vascular endothelial growth factor in the human retina and in nonproliferative diabetic retinopathy. Am J Pathol 1998; 152: 1453-1462.
27. Rakoczy PE, Brankov M, Fonceca A, Zaknich T, Rae BC, Lai CM. Enhanced recombinant adeno-associated virus-mediated vascular endothelial growth factor expression in the adult mouse retina: a potential model for diabetic retinopathy. Diabetes 2003; 52: 857-863.
28. Vinores SA, Derevjanik NL, Vinores MA, Okamoto N, Campochiaro PA. Sensitivity of different vascular beds in the eye to neovascularization and blood-retinal barrier breakdown in VEGF transgenic mice. Adv Exp Med Biol 2000; 476: 129-138.
29. Frank RN, Amin RH, Eliott D, Puklin JE, Abrams GW. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol 1996; 122: 393-403.
30. Tombran-Tink J, Chader GG, Johnson LV. PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity. Exp Eye Res 1991; 53: 411-414.
31. Ogata N, Wada M, Otsuji T, Jo N, Tombran-Tink J, Matsumura M. Expression of pigment epithelium-derived factor in normal adult rat eye and experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 2002; 43: 1168-1175. (Pubitemid 34258289)
32. Aymerich MS, Alberdi EM, Martinez A, Becerra SP. Evidence for pigment epithelium-derived factor receptors in the neural retina. Invest Ophthalmol Vis Sci 2001; 42: 3287-3293.
33. Duh EJ, Yang HS, Suzuma I, Miyagi M, Youngman E, Mori K, Katai M, Yan L, Suzuma K, West K, Davarya S, Tong P, Gehlbach P, Pearlman J, Crabb JW, Aiello LP, Campochiaro PA, Zack DJ. Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Invest Ophthalmol Vis Sci 2002; 43: 821-829.
34. Boehm BO, Lang G, Feldmann B, Kurkhaus A, Rosinger S, Volpert O, Lang GK, Bouck N. Proliferative diabetic retinopathy is associated with a low level of the natural ocular anti-angiogenic agent pigment epithelium-derived factor (PEDF) in aqueous humor. A pilot study. Horm Metab Res 2003; 35: 382-386. (Pubitemid 37102685)
35. Boehm BO, Lang G, Volpert O, Jehle P M, Kurkhaus A, Rosinger S, Lang GK, Bouck N. Low content of the natural ocular antiangiogenic agent pigment epithelium-derived factor (PEDF) in aqueous humor predicts progression of diabetic retinopathy. Diabetologia 2003; 46: 394-400. (Pubitemid 36547595)
36. Gao G, Li Y, Fant J, Crosson CE, Becerra SP, Ma JX. Difference in ischemic regulation of vascular endothelial growth factor and pigment epithelium-derived factor in brown Norway and Sprague Dawley rats contributing to different susceptibilities to retinal neovascularization. Diabetes 2002; 51: 1218-1225.
37. Nicholls MG, Richards AM, Agarwal M. The importance of the renin-angiotensin system in cardiovascular disease. J Hum Hypertens 1998; 12: 295-299.
38. Kato H, Suzuki H, Tajima S, Ogata Y, Tominaga T, Sato A, Saruta T. Angiotensin II stimulates collagen synthesis in cultured vascular smooth muscle cells. J Hypertens 1991; 9: 17-22.
39. Otani A, Takagi H, Suzuma K, Honda Y. Angiotensin II potentiates endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res 1998; 82: 619-628.
40. Danser AHJ, van den Dorpel MA, Deinum J, Derkx FHM, Franken AAM, Peperkamp E, de Jong PTVM, Schalekamp MADH. Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinoapthy. J Clin Endocrinol Metab 1989; 68: 160-167.
41. Danser AH, Derkx FH, Admiraal J, Deinum J, de Jong PT, Schalekamp MA. Angiotensin levels in the eye. Invest Ophthalmol Vis Sci 1994; 35: 1008-1018.
42. Danser AH. Local renin-angiotensin systems: the unanswered questions. Int J Biochem Cell Biol 2003; 35: 759-768.
43. Deinum J, Derkx FH, Danser AH, Schalekamp MA. Indentification and quantification of renin and prorenin in the bovine eye. Endocrinol 1990; 126: 1673-1682.
44. Deinum J, Tarnow L, van Gool JM, de Bruin RA, Derkx FHM, Schalekamp MADH, Parving H-H. Plasma renin and prorenin and renin gene variation in patiens with insulin-dependent diabetis mellitus and nephropathy. Nephrol Dial Transplant 1999; 14: 1904-1911.
45. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000; 52: 11-34.
46. Jacobi PC, Osswald H, Jurklies B, Zrenner E. Neuromodulatory effects of the reninangiotensin system on the cat electroretinogram. Invest Ophthalmol Vis Sci 1994; 35: 973-980.
47. Border WA, Noble NA. Interactions of transforming growth factor-β and angiotensin II in renal fibrosis. Hypertension 1998; 31: 181-188.
48. Du J, Peng T, Scheidegger K, Delafontaine P. Angiotensin II activation of insulin-like growth factor 1 receptor transcription is mediated by a tyrosine kinase-dependent redox-sensitive mechanism. Arterioscler Thromb Vasc Biol 1999; 19: 2119-2126.
49. Ferrari-Dileo G, Davis EB, Anderson DR. Angiotensin II binding receptors in retinal and optic nerve head blood vessels. An autoradiographic approach. Invest Ophthalmol Vis Sci 1991; 32: 21-26.
50. Kawamura H, Kobayashi M, Li Q, Yamanishi S, Katsumura K, Minami M, Wu DM, Puro DG. Effects of angiotensin II on the pericyte-containing microvasculature of the rat retina. J Physiol 2004; 561: 671-683.
51. Nadal JA, Scicli GM, Carbini LA, Scicli AG. Angiotensin II stimulates migration of retinal microvascular pericytes: involvement of TGF-beta and PDGF-BB. Am J Physiol Heart Circ Physiol 2002; 282: H739-H748.
52. Schonfelder U, Hofer A, Paul M, Funk RH. In situ observation of living pericytes in rat retinal capillaries. Microvasc Res 1998; 56: 22-29.
53. Fernandez LA, Twickler J, Mead A. Neovascularization produced by angiotensin II. J Lab Clin Med 1985; 105: 141-145.
54. Le Noble FA, Hekking JW, Van Straaten HW, Slaaf DW, Struyker Boudier HA. Angiotensin II stimulates angiogenesis in the chorio-allantoic membrane of the chick embryo. Eur J Pharmacol 1991; 195: 305-306.
55. Egami K, Murohara T, Shimada T, Sasaki K-I, Shintani S, Sugaya T, Ishii M, Akagi T, Ikeda H, Matsuishi T, Imaizumi T. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 2003; 112: 67-75.
56. Rong P, Wilkinson-Berka JL, Skinner SL. Renin in thymus, gut, hindlimb, and adrenal of (mRen-2) 27 and normal rats: secretion and content studies. Am J Physiol 1999; 277: E639-E646.
57. Wilkinson-Berka JL, Kelly DJ, Rong P, Campbell DJ, Skinner SL. Characterisation of a thymic renin-angiotensin system in the transgenic m (Ren-2) 27 rat. Mol Cell Endocrinol 2002; 194: 201-209.
58. Wagner J, Jan Danser AH, Derkx FH, de Jong TV, Paul M, Mullins JJ, Schalekamp MA, Ganten D. Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system. Br J Ophthalmol 1996; 80: 159-163.
59. Brandt CR, Pumfery AM, Micales B, Bindley CD, Lyons GE, Sramek SJ, Wallow IH. Renin mRNA is synthesized locally in rat ocular tissues. Curr Eye Res 1994; 13: 755-763.
60. Berka JL, Stubbs AJ, Wang DZ-M, Di Nicolantonio R, Alcorn D, Campbell DJ, Skinner S. Renin-containing Müller cells of the retina display endocrine features. Invest Ophthalmol Vis Sci 1995; 36: 1450-1458.
61. Tout S, Chan-Ling T, Hollander H, Stone J. The role of Müller cells in the formation of the blood-retinal barrier. Neuroscience 1993; 55: 291-301.
62. Moravski CJ, Skinner SL, Stubbs AJ, Sarlos S, Kelly DJ, Cooper ME, Gilbert RE, Wilkinson-Berka JL. The renin-angiotensin system influences ocular endothelial cell proliferation in diabetes: transgenic and interventional studies. Am J Pathol 2003; 162: 151-160.
63. Luetscher JA, Kraemer FB, Wilson DM, Schwartz HC, Bryer-Ash M. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N Engl J Med 1985; 312: 1412-1417.
64. Franken AA, Derkx FH, Schalekamp MA, Manint' Veld AJ, Hop WC, van Rens EH, de Jong PT. Association of high plasma prorenin with diabetic retinopathy. J Hypertens 1988; 6 Suppl: S461-S463.
65. Allen TJ, Cooper ME, Gilbert RE, Winikoff J, Skinnier SL, Jerums G. Serum total renin is increased before microalbuminuria in diabetes. Kidney Int 1996; 50: 902-907.
66. Zhang JZ, Gao L, Widness M, Xi X, Kern TS. Captopril inhibits glucose accumulation in retinal cells in diabetes. Invest Ophthalmol Vis Sci 2003; 44: 4001-4005.
67. Gilbert RE, Kelly DJ, Cox AJ, Wilkinson-Berka JL, Rumble JR, Osicka T, Panagiotopoulos S, Lee V, Hendrich EC, Jerums G, Cooper ME. Angiotensin converting enzyme inhibition reduces retinal over-expression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia 2000; 43: 1360-1367.
68. Horio N, Clermont AC, Abiko A, Abiko T, Shoelson BD, Bursell SE, Feener EP. Angiotensin AT (1) receptor antagonism normalizes retinal blood flow and acetylcholine-induced vasodiliation in normotensive diabetic rats. Diabetologia 2004; 47: 113-123.
69. Engerman R, Finkelstein D, Aguirre G, Diddie KR, Fox RR, Frank RN, Varma SD. Ocular complications. Diabetes 1982;31(Suppl 1 Pt 2):82-88.
70. Kelly DJ, Wilkinson-Berka JL, Allen TA, Cooper ME, Skinner SL. A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2) 27 rat. Kidney Int 1998; 54: 343-352.
71. Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 1990;344(6266):541-544.
72. Wheeler-Schilling TH, Kohler K, Sautter M, Guenther E. Angiotensin II receptor subtype gene expression and cellular localization in the retina and non-neuronal ocular tissues of the rat. Eur J Neurosci 1999; 11: 3387-3394.
73. Bui BV, Armitage JA, Tolcos M, Cooper ME, Vingrys AJ. ACE inhibition salvages the visual loss caused by diabetes. Diabetologia 2003; 46: 401-408.
74. John WG, Lamb EJ. The Maillard or browning reaction in diabetes. Eye 1993; 7: 230-237.
75. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991; 325: 836-842.
76. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001; 44: 129-146.
77. Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 1991; 88: 11555-11558.
78. Stitt AW. The role of advanced glycation in the pathogenesis of diabetic retinopathy. Exp Mol Pathol 2003; 75: 95-108.
79. Hammes HP, Alt A, Niwa T, Clausen JT, Bretzel RG, Brownlee M, Schleicher ED. Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. Diabetologia 1999; 42: 728-736.
80. Chiarelli F, de Martino M, Mezzetti A, Catino M, Morgese G, Cuccurullo F, Verrotti A. Advanced glycation end products in children and adolescents with diabetes: relation to glycemic control and early microvascular complications. J Pediatr 1999; 134: 486-491.
81. Tomlinson DR, Mitogen-activated protein kinases as glucose transducers for diabetic complications. Diabetologia 1999; 42: 1271-1281.
82. Ishii H, Koya D, King GL. Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. J Mol Med 1998; 76: 21-31.
83. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998; 47: 859-866.
84. Lee TS, MacGregor LC, Fluharty SJ, King GL. Differential regulation of protein kinase C and (Na, K) -adenosine triphosphatase activities by elevated glucose levels in retinal capillary endothelial cells. J Clin Invest 1989; 83: 90-94.
85. Osicka TM, Yu Y, Lee V, Panagiotopoulos S, Kemp BE, Jerums G. Aminoguanidine and ramipril prevent diabetes-induced increases in protein kinase C activity in glomeruli, retina and mesenteric artery. Clin Sci (Lond) 2001; 100: 249-257.
86. Xia P, Aiello LP, Ishii H, Jiang ZY, Park DJ, Robinson GS, Takagi H, Newsome WP, Jirousek MR, King GL. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 1996; 98: 2018-2026.
87. Aiello LP, Bursell SE, Clermont A, Duh E, Ishii H, Takagi C, Mori F, Ciulla TA, Ways K, Jirousek M, Smith LE, King GL. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997; 46: 1473-1480. (Pubitemid 27369086)
88. Kowluru RA, Jirousek MR, Stramm L, Farid N, Engerman RL, Kern TS. Abnormalities of retinal metabolism in diabetes or experimental galactosemia: V. Relationship between protein kinase C and ATPases. Diabetes 1998; 47: 464-469.
89. Bloodworth JM Jr. Diabetic retinopathy. Diabetes 1962; 11: 1-22.
90. Ewing FM, Deary IJ, Strachan MW, Frier BM. Seeing beyond retinopathy in diabetes: electrophysiological and psychophysical abnormalities and alterations in vision. Endocr Rev 1998; 19: 462-476.
91. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 1998; 102: 783-791.
92. Park SH, Park JW, Park SJ, Kim KY, Chung JW, Chun MH, Oh SJ. Apoptotic death of photoreceptors in the streptozotocininduced diabetic rat retina. Diabetologia 2003; 46: 1260-1268.
93. Martin PM, Roon P, Van Ells TK, Ganapathy V, Smith SB. Death of retinal neurons in streptozotocin-induced diabetic mice. Invest Ophthalmol Vis Sci 2004; 45: 3330-3336.
94. Aizu Y, Oyanagi K, Hu J, Nakagawa H. Degeneration of retinal neuronal processes and pigment epithelium in the early stage of the streptozotocin- diabetic rats. Neuropathology 2002; 22: 161-170.
95. Granit R. Components of the retinal action potential in mammals and their relations to the discharge in the optic nerve. J Physiol (Lond) 1933; 77: 207-238.
96. Yonemura D, Aoki T, Tsuzuki K. Electroretinogram in diabetic retinopathy. Arch Ophthalmol 1962; 68: 19-24.
97. Frost-Larsen K, Larsen H. Macular recovery time recorded by nyctometry-a screening method for selection of patients who are at risk of developing proliferative diabetic retinopathy. Results of a 5-year follow up. Acta Ophthalmol Scand 1985;63(Suppl 173):39-47.
98. Sakai H, Tani Y, Shirasawa E, Shirao Y, Kawasaki K. Development of electroretinographic alterations in streptozotocininduced diabetes in rats. Ophthalmic Res 1995; 27: 57-63.
99. Simonsen SE. ERG in diabetes. In: The Clinical Value of Electroretinography, ISERG Symposium. Ghent: Basel; 1966.
100. Simonsen SE. The value of the oscillatory potential in selecting juvenile diabetics at risk of developing proliferative retinopathy. Acta Ophthalmol Scand 1980; 58: 865-878.
101. Hancock HA, Kraft TW. Oscillatory potential analysis and ERGs of normal and diabetic rats. Invest Ophthalmol Vis Sci 2004; 45: 1002-1008.
102. Li Q, Puro DG. Diabetes-induced dysfunction of the glutamate transporter in retinal Müller cells. Invest Ophthalmol Vis Sci 2002; 43: 3109-3116.
103. Shirao Y, Kawasaki K. Electrical responses from diabetic retina. Prog Retin Eye Res 1998; 17: 59-76.
104. Li Q, Zemel E, Miller B, Perlman I. Early retinal damage in experimental diabetes: electroretinographical and morphological observations. Exp Eye Res 2002; 74: 615-625.
105. Ames A, Li YY, Heher EC, Kimble CR. Energy metabolism of rabbit retina as related to function: high cost of Na+transport. J Neurosci 1992; 12: 840-853.
106. Phipps JA, Fletcher EL, Vingrys AJ. Paired-flash identification of rod and cone dysfunction in the diabetic rat. Invest Ophthalmol Vis Sci. In press.
107. Holopigian K, Greenstein VC, Seiple W, Hood DC, Carr RE. Evidence for photoreceptor changes in patients with diabetic retinopathy. Invest Ophthalmol Vis Sci 1997; 38: 2355-2365.
108. Pautler EL, Ennis SR. The effect of induced diabetes on the electroretinogram components of the pigmented rat. Invest Ophthalmol Vis Sci 1980; 19: 702-705.
109. Schneck ME, Fortune B, Adams AJ. The fast oscillation of the electro-oculogram reveals sensitivity of the human outer retina/retinal pigment epithelium to glucose level. Vision Res 2000; 40: 3447-3453.
110. Tsacopoulos M, Poitry-Yamate CL, MacLeish PR, Poitry S. Trafficking of molecules and metabolic signals in the retina. Prog Retin Eye Res 1998; 17: 429-442.
111. Ennis SR, Johnson JE, Pautler EL. In situ kinetics of glucose transport across the blood-retinal barrier in normal rats and rats with streptozocin-induced diabetes. Invest Ophthalmol Vis Sci 1982; 23: 447-456.
112. Verrotti A, Lobefalo L, Petitti M T, Mastropasqua L, Morgese G, Chiarelli F, Gallenga PE. Relationship between contrast sensitivity and metabolic control in diabetics with and without retinopathy. Ann Med 1998; 30: 369-374.
113. Arden GB, Wolf JE, Tsang Y. Does dark adaptation exacerbate diabetic retinopathy? Evidence and a linking hypothesis. Vision Res 1998; 38: 1723-1729.
114. Dean FM, Arden GB, Dornhorst A. Partial reversal of protan and tritan colour defects with inhaled oxygen in insulin dependent diabetic subjects. Br J Ophthalmol 1997; 81: 27-30.
115. Frost-Larsen K, Larsen H, Simonsen S. Oscillatory potential and pyctometry in insulin-dependent diabetics. Acta Ophthalmol Scand 1980; 58: 879-888.
116. Vadala M, Anastasi M, Lodato G, Cillino S. Electroretinographic oscillatory potentials in insulin-dependent diabetes patients: a long-term follow-up. Acta Ophthalmol Scand 2002; 80: 305-309.
117. Fortune B, Schneck ME, Adams AJ. Multifocal electroretinogram delays reveal local retinal dysfunction in early diabetic retinopathy. Invest Ophthalmol Vis Sci 1999; 40: 2638-2651.
118. Han Y, Bearse MA Jr, Schneck ME, Barez S, Jacobsen CH, Adams AJ. Multifocal electroretinogram delays predict sites of subsequent diabetic retinopathy. Invest Ophthalmol Vis Sci 2004; 45: 948-954.
119. Ripps H, Witkovsky P. Neuron-glia interaction in the brain and retina. In: Chader GG, Osborne NN, eds. Progress in Retina and Eye Research. Oxford: Pergamon Press; 1985. p 181-219.
120. Nork TM, Wallow IH, Sramek SJ, Anderson G. Müller's cell involvement in proliferative diabetic retinopathy. Arch Ophthalmol 1987; 105: 1424-1429.
121. Lieth E, Barber AJ, Xu B, Dice C, Ratz MJ, Tanase D, Strother JM. Glial reactivity and impaired glutamate metabolism in shortterm experimental diabetic retinopathy. Penn State Retina Research Group. Diabetes 1998; 47: 815-820. (Pubitemid 28201813)
122. Rungger-Brändle E, Dosso AA, Leuenberger PM. Glial reactivity, an early feature of diabetic retinopathy. Invest Ophthalmol Vis Sci 2000; 41: 1971-1980.
123. Barber AJ, Antonetti DA, Gardner TW. Altered expression of retinal occludin and glial fibrillary acidic protein in experimental diabetes. The Penn State Retina Research Group. Invest Ophthalmol Vis Sci 2000; 41: 3561-3568.
124. Erickson P, Fisher S, Guerin C, Anderson D, Kaska D. Glial fibrillary acidic protein increases in Müller cells after retinal detachment. Exp Eye Res 1987; 44: 37-48.
125. Eisenfeld A, Bunt-Milam A, Vijay Sarthy P. Müller cells expression of glial fibrillary acidic protein after genetic and experimental photoreceptor degeneration in the rat retina. Invest Ophthalmol Vis Sci 1984; 25: 1321-1328.
126. Bignami A, Dahl D. The radial glia of Müller in the rat retina and their response to injury. An immunofluorescence study with antibodies to the glial fibrillary acidic protein. Exp Eye Res 1979; 28: 63-69.
127. Kalloniatis M, Tomisich G. Amino acid neurochemistry of the vertebrate retina. Prog Retin Eye Res 1999; 18: 811-866.
128. Ehinger B. Glial and neuronal uptake of GABA, glutamic acid, glutamine and glutathione in the rabbit retina. Exp Eye Res 1977; 25: 221-234.
129. Rauen T, Rothstein JD, Wassle H. Differential expression of three glutamate transporter subtypes in the rat retina. Cell Tissue Res 1996; 286: 325-336.
130. Rauen T, Taylor WR, Kuhlbrodt K, Wiessner M. High-affinity glutamate transporters in the rat retina: a major role of the glial glutamate transporter GLAST-1 in transmitter clearance. Cell Tissue Res 1998; 291: 19-31.
131. Pow DV, Robinson SR. Glutamate in some retinal neurons is derived solely from glia. Neuroscience 1994; 60: 355-366.
132. Pow DV, Crook DK. Direct immunocytochemical evidence for the transfer of glutamine from glial cells to neurons: use of specific antibodies directed against the d-stereoisomers of glutamate and glutamine. Neuroscience 1996; 70: 295-302.
133. Barnett NL, Pow DV. Antisense knockdown of GLAST, a glial glutamate transporter, compromises retinal function. Invest Ophthalmol Vis Sci 2000; 41: 585-591.
134. Fletcher EL, Kalloniatis M. Neurochemical architecture of the normal and degenerating rat retina. J Comp Neurol 1996; 376: 343-360. (Pubitemid 26419112)
135. Ambati J, Chalam KV, Chawla DK, D'Angio CT, Guillet EG, Rose SJ, Vanderlinde RE, Ambati BK. Elevated gamma-aminobutyric acid, glutamate, and vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol 1997; 115: 1161-1166.
136. Ward MM, Jobling AI, Kalloniatis M, Fletcher EL. Glutamate uptake in retinal glial cells during diabetes. Diabetologia 2005; 48: 351-360.
137. Ishikawa A, Ishiguro S, Tamai M. Accumulation of gamma-aminobutyric acid in diabetic rat retinal Müller cells evidenced by electron microscopic immunocytochemistry. Curr Eye Res 1996; 15: 958-964.
138. Ishikawa A, Ishiguro S, Tamai M. Changes in GABA metabolism in streptozotocininduced diabetic rat retinas. Curr Eye Res 1996; 15: 63-71.
139. Ponjavic V, Granse L, Kjellstrom S, Andreasson S, Bruun A. Alterations in electroretinograms and retinal morphology in rabbits treated with vigabatrin. Doc Ophthalmol 2004; 108: 125-133.
140. Duboc A, Hanoteau N, Simonutti M, Rudolf G, Nehlig A, Sahel JA, Picaud S. Vigabatrin, the GABA-transaminase inhibitor, damages cone photoreceptors in rats. Ann Neurol 2004; 55: 695-705.
141. Banin E, Shalev RS, Obolensky A, Neis R, Chowers I, Gross-Tsur V. Retinal function abnormalities in patients treated with vigabatrin. Arch Ophthalmol 2003; 121: 811-816.
142. Ling T, Mitrofanis J, Stone J. Origin of retinal astrocytes in the rat: evidence of migration from the optic nerve. J Comp Neurol 1989; 286: 345-352.
143. Stone J, Dreher Z. Relationship between astrocytes, ganglion cells and vasculature of the retina. J Comp Neurol 1987; 255: 35-49.
144. Aiello LM, Perspectives on diabetic retinopathy. Am J Ophthalmol 2003; 136: 122-135.
145. Klein BE, Klein R, Moss SE, Palta M. A cohort study of the relationship of diabetic retinopathy to blood pressure. Arch Ophthalmol 1995; 113: 601-606.
146. Kern TS Engerman RL. Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. Diabetes 2001; 50: 1636-1642.
147. Kowluru RA, Engerman RL, Kern TS. Abnormalities of retinal metabolism in diabetes or experimental galactosemia VIII. Prevention by aminoguanidine. Curr Eye Res 2000; 21: 814-819.
148. Freedman BI, Wuerth JP, Cartwright K, Bain RP, Dippe S, Hershon K, Mooradian AD, Spinowitz BS. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials 1999; 20: 493-510.
149. Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB, Cartwright K, Foiles PG, Freedman BI, Raskin P, Ratner RE, Spinowitz BS, Whittier FC, Wuerth JP. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004; 24: 32-40.
150. Xu X, Zhu Q, Xia X, Zhang S, Gu Q, Luo D. Blood-retinal barrier breakdown induced by activation of protein kinase C via vascular endothelial growth factor in streptozotocin-induced diabetic rats. Curr Eye Res 2004; 28: 251-256.
151. Danis RP, Bingaman DP, Jirousek M, Yang Y. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531. Invest Ophthalmol Vis Sci 1998; 39: 171-179.
152. Davis MD, Aiello LP, Milton RC, Sheetz MJ, Arora V, Vignati L. Diabetic retinopathy and macula edema progression rates in recent placebo-controlled clinical trials. Diabetes 2003; 52: A200.
153. Milton RC, Aiello LP, Davis MD, Arora V, Vignati L, Sheetz MJ. Initial results of the Protein Kinase C-Beta Inhibitor Diabetic Retinopathy Study (PKC-DRS). Diabetes 2003; 52: A127.
154. Hogeboom van Buggenum IM, Polak BC, Reichert-Thoen JW, de Vries-Knoppert WA, van Hinsbergh VW, Tangelder GJ. Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy. Diabetologia 2002; 45: 203-209.
155. Lo TC, Klunder L, Fletcher EL. Increased Müller cell density during diabetes is ameliorated by aminoguanidine and ramipril. Clin Exp Optom 2001; 84: 276-281.
156. Nagisa Y, Shintani A, Nakagawa S. The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats. Diabetologia 2001; 44: 883-888.
157. Moravski CJ, Kelly DJ, Cooper ME, Gilbert RE, Bertram JF, Shahinfar S, Skinner SL, Wilkinson-Berka JL. Retinal neovascularization is prevented by blockade of the renin-angiotensin system. Hypertension 2000; 36: 1099-1104.
158. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive Type 2 diabetic patients. Ann Intern Med 1993; 118: 577-581.
159. Ravid M, Savin H, Lang R, Jutrin I, Shoshana L, Lishner M. Proteinuria, renal impairment, metabolic control, and blood pressure in type 2 diabetes mellitus. A 14-year follow-up report on 195 patients. Arch Intern Med 1992; 152: 1225-1229.
160. Larsen M, Hommel E, Parving HH, Lund-Andersen H. Protective effect of captopril on the blood-retina barrier in normotensive insulin-dependent diabetic patients with nephropathy and background retinopathy. Graefes Arch Clin Exp Ophthalmol 1990; 228: 505-509.
161. Chase HP, Garg SK, Harris S, Hoops S, Jackson WE, Holmes DL. Angiotensin-converting enzyme inhibitor treatment for young normotensive diabetic subjects: a two-year trial. Ann Ophthalmol 1993; 25: 284-289.
162. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet 1997;349(9068):1787-1792.
163. Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, Rogulja-Pepeonik Z, Fuller JH. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998;351(9095):28-31.
164. Chaturvedi N, Sjoelie A K, Svensson A. The diabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design. J Renin Angiotensin Aldosterone Syst 2002; 3: 255-261.